Investigating the human protein-host protein interactome of SARS-CoV-2 infection in the small intestine
Gastroenterology and Hepatology from Bed to Bench,
20 September 2020
Deciphering the tissue and organ interactions of the SARS-CoV-2 can be important to discern the potential underlying mechanisms and characterize drug candidates. Gastrointestinal symptoms and inflammation were frequently reported in the coronavirus disease 2019 (COVID-19). The expression pattern of ACE2 in the small intestinal as a major host receptor for SARS-CoV-2 and digestion-related enzyme has been determined. Here, we investigated interactome of the SARS-CoV-2–host protein in the small intestine tissue to detect highly clustered modules and associated mechanisms. 13 primary protein neighbors were found for ACE2 among the small intestine-specific proteins. The first module with the highest score was found as key module, since ACE2 and its four partners were observed in this module. Moreover, 8 host proteins were belonged to the highly clustered module. Functional analysis of this module highlighted protein digestion and absorption as a significant KEGG pathway with enriched genes of ACE2, MEP1A, MEP1B, DPP4, and XPNPEP2. Regulatory network revealed possible upstream regulating transcription factors that HNF factors including HNF4A, HNF1A, and HNF1B were found to be regulating the expression of ACE2 target gene. Drug-target interactions revealed associated drug classes. The SARS-CoV-2–host protein interactome revealed the important elements for virus infection in the small intestine that may help to clarify gastrointestinal symptoms and inflammation.
- SARS-CoV-2, small intestine, protein interaction network, regulatory network, drug targets, interactome
2. Organization, W.H. Statement on the Second Meeting of the International Health Regulations. Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV); 2005. in URL: https://www. who. int/news-room/detail/30-01-2020-statement-onthe-second-meeting-of-the-international-health-regulations. 2005.
3. Li, Q., et al., Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine, 2020.
4. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 2020. 395(10223): p. 497-506.
5. Fang, Z., et al., Clinical characteristics of 2019 coronavirus pneumonia (COVID-19): an updated systematic review. MedRxiv, 2020.
6. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020. 395(10223): p. 507-513.
7. Xu, X., et al., Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. European journal of nuclear medicine and molecular imaging, 2020: p. 1-6.
8. Chan, J.F.-W., et al., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet, 2020. 395(10223): p. 514-523.
9. Zhou, P., et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature, 2020. 579(7798): p. 270-273.
10. Hamming, I., et al., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 2004. 203(2): p. 631-637.
11. Nikhra, V., The Agent and Host Factors in Covid-19: Exploring Pathogenesis and Therapeutic Implications.
12. Kuba, K., et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature medicine, 2005. 11(8): p. 875-879.
13. Hashimoto, T., et al., ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature, 2012. 487(7408): p. 477-481.
14. Li, Z., et al., Discovery of potential drugs for COVID-19 based on the connectivity map. 2020.
15. Feng, Z., Y. Wang, and W. Qi, The small intestine, an underestimated site of SARS-CoV-2 infection: from red queen effect to probiotics. Preprints, 2020.
16. Liang, W., et al., Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut, 2020. 69(6): p. 1141-1143.
17. Zhang, H., et al., Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. International Journal of Infectious Diseases, 2020.
18. Liu, X., et al., TiGER: a database for tissue-specific gene expression and regulation. BMC bioinformatics, 2008. 9(1): p. 1-7.
19. Gheblawi, M., et al., Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circulation research, 2020. 126(10): p. 1456-1474.
20. Wicik, Z., et al., ACE2 interaction networks in COVID-19: a physiological framework for prediction of outcome in patients with cardiovascular risk factors. BioRxiv, 2020.
21. Karunakaran, K.B., N. Balakrishnan, and M.K. Ganapathiraju, Interactome of SARS-CoV-2/nCoV19 modulated host proteins with computationally predicted PPIs. 2020.
22. Consortium, U., UniProt: a worldwide hub of protein knowledge. Nucleic acids research, 2019. 47(D1): p. D506-D515.
23. Stelzer, G., et al., The GeneCards suite: from gene data mining to disease genome sequence analyses. Current protocols in bioinformatics, 2016. 54(1): p. 1.30. 1-1.30. 33.
24. Szklarczyk, D., et al., STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic acids research, 2019. 47(D1): p. D607-D613.
25. Hoffmann, M., et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020.
26. Gordon, D., et al., A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug Repurposing. bioRxiv. 2020. 03.22. 002386. 2020.
27. Kumar, R., et al., Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Reveals Mosaic Pattern of Phylogeographical Distribution. Msystems, 2020. 5(4).
28. Dennis, G., et al., DAVID: database for annotation, visualization, and integrated discovery. Genome biology, 2003. 4(9): p. 1-11.
29. Shannon, P., et al., Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research, 2003. 13(11): p. 2498-2504.
30. Bader, G.D. and C.W. Hogue, An automated method for finding molecular complexes in large protein interaction networks. BMC bioinformatics, 2003. 4(1): p. 2.
31. Kanehisa, M., et al., KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic acids research, 2017. 45(D1): p. D353-D361.
32. Stöckel, D., et al., Multi-omics enrichment analysis using the GeneTrail2 web service. Bioinformatics, 2016. 32(10): p. 1502-1508.
33. Matys, V., et al., TRANSFAC®: transcriptional regulation, from patterns to profiles. Nucleic acids research, 2003. 31(1): p. 374-378.
34. Becker, K.G., et al., The genetic association database. Nature genetics, 2004. 36(5): p. 431-432.
35. Brown, A.S. and C.J. Patel, A standard database for drug repositioning. Scientific data, 2017. 4(1): p. 1-7.
36. Szklarczyk, D., et al., STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data. Nucleic acids research, 2016. 44(D1): p. D380-D384.
37. Zhang, H., et al., Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine, 2020. 46(4): p. 586-590.
38. Mönkemüller, K., L. Fry, and S. Rickes, COVID-19, coronavirus, SARS-CoV-2 and the small bowel. Rev Esp Enferm Dig, 2020. 112(5): p. 383-388.
39. Camargo, S.M., et al., Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. Gastroenterology, 2009. 136(3): p. 872-882. e3.
40. Arnold, P., A. Otte, and C. Becker-Pauly, Meprin metalloproteases: molecular regulation and function in inflammation and fibrosis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2017. 1864(11): p. 2096-2104.
41. Vazeille, E., et al., Role of meprins to protect ileal mucosa of Crohn's disease patients from colonization by adherent-invasive E. coli. PloS one, 2011. 6(6): p. e21199.
42. Strollo, R. and P. Pozzilli, DPP4 inhibition: preventing SARS‐CoV‐2 infection and/or progression of COVID‐19? Diabetes/Metabolism Research and Reviews, 2020.
43. Olivares, M., et al., The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health. Frontiers in microbiology, 2018. 9: p. 1900.
44. Solerte, S.B., et al., Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetologica, 2020: p. 1.
45. Pereira, J.A.d.S., F.C.d. Silva, and P.M.M. de Moraes-Vieira, The impact of ghrelin in metabolic diseases: an immune perspective. Journal of diabetes research, 2017. 2017.
46. El-Salhy, M., Ghrelin in gastrointestinal diseases and disorders: a possible role in the pathophysiology and clinical implications. International journal of molecular medicine, 2009. 24(6): p. 727-732.
47. Chen, L., et al., Identification of transcription factors regulating SARS-CoV-2 entry genes in the intestine. Cellular and Molecular Gastroenterology and Hepatology, 2020.
48. Pedersen, K.B., et al., The transcription factor HNF1α induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from evolutionarily conserved promoter motifs. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 2013. 1829(11): p. 1225-1235.
49. Barker, H. and S. Parkkila, Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2. BioRxiv, 2020.
50. Gendron, F.-P., et al., The CDX2 transcription factor regulates furin expression during intestinal epithelial cell differentiation. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2006. 290(2): p. G310-G318.
51. Guo, Y., et al., Preliminary clinical study of direct renin inhibitor aliskiren in the treatment of severe COVID-19 patients with hypertension. Zhonghua nei ke za zhi, 2020. 59: p. E011-E011.
52. Aly, O.M., Molecular docking reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and metamizole to inhibit COVID-19 virus main protease. 2020.
53. Valencia, I., et al., DPP4 and ACE2 in diabetes and COVID-19: therapeutic targets for cardiovascular complications? Frontiers in Pharmacology, 2020. 11: p. 1161.
54. Goto, M., et al., Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport. Journal of diabetes investigation, 2018. 9(6): p. 1261-1269.
55. Elkahloun, A.G. and J.M. Saavedra, Candesartan could ameliorate the COVID-19 cytokine storm. Biomedicine & Pharmacotherapy, 2020: p. 110653.
56. Wu, D., et al., Candesartan attenuates hypertension-associated pathophysiological alterations in the gut. Biomedicine & Pharmacotherapy, 2019. 116: p. 109040.
57. Gurwitz, D., Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics. Drug development research, 2020.
58. Rothlin, R.P., et al., Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID‐19. Drug Development Research, 2020.
59. Arab, H.H., et al., Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease. PloS one, 2014. 9(5): p. e97193.
60. Gommans, D.F., et al., Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease. American Heart Journal, 2020.
61. Skayem, C. and N. Ayoub, Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity. The American Journal of the Medical Sciences, 2020.
62. Das, U.N., Bioactive Lipids as Mediators of the Beneficial Action (s) of Mesenchymal Stem Cells in COVID-19. Aging and disease, 2020: p. 0.
63. Castaldo, N., et al., Safety and efficacy of amiodarone in a patient with COVID-19. JACC: Case Reports, 2020. 2(9): p. 1307-1310.
- Abstract Viewed: 0 times